Immunic CEO on key 2025 highlights and 2026 milestones

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive's Stephen Gunnion about the company’s major milestones in 2025 and key expectations for 2026. He highlighted the significance of the phase 2 CALLIPER study, which demonstrated a 31% reduction in confirmed disability worsening in patients with primary progressive multiple sclerosis (MS), and a 34% reduction in those without baseline gadolinium lesions. According to Vitt, this points to a “neuroprotective effect” of vidofludimus calcium. He also noted consistent long-term results from the phase 2 EMPhASIS study, where 92.3% of relapsing-remitting MS patients remained free of 12-week confirmed disability worsening after 144 weeks. Only 13.8% of in total 29 disability events were progression independent of relapse activity (PIRA), supporting the drug’s potential effect on progression regardless of relapse activity. Beyond MS, Vitt said Immunic has strengthened its patent position for vidofludimus calcium, with potential exclusivity to 2041 in key markets. He also discussed early findings on IMU-856, which showed increases in natural GLP-1 levels—suggesting gut health benefits and potential links to weight management. Looking ahead, the company expects top-line data from the phase 3 ENSURE trials by the end of 2026. Vitt said, “That’s a big step for the company forward to getting vidofludimus calcium ready to be launched and ready to be submitted for approval to the FDA.” Visit Proactive’s YouTube channel for more interviews and updates. Don’t forget to like the video, subscribe, and turn on notifications for future content. #ImmunicInc #MultipleSclerosis #VidofludimusCalcium #MSResearch #BiotechStocks #FDAApproval #ClinicalTrials #CeliacDisease #GLP1 #Neuroprotection #Biopharma #HealthcareInnovation #DrugDevelopment #MSAwareness #InvestorUpdate